Urinary gelatinase activities (matrix metalloproteinases 2 and 9) in human bladder tumors
- PMID: 16596205
Urinary gelatinase activities (matrix metalloproteinases 2 and 9) in human bladder tumors
Abstract
The ability to degrade type IV collagen, the major component of the basement membrane, is unique to gelatinases A and B. These two matrix metalloproteinases (MMPs) are most often linked to the malignant phenotype of tumor cells, and their expression is elevated in several cases of human tumor aggressiveness and overall survival. By gelatin zymography, we verified MMP activity in the urine of patients with bladder cancer. Of these patients, 10 had well-, 8 had moderately and 7 had poorly differentiated bladder cancer. The urine of healthy volunteers with no evidence of disease was used for controls. Zymography showed five dominant gelatinolytic bands of 240, 220, 130, 92 and 72 kDa in tumor samples, whereas only traces of MMP were detected in the urine of healthy subjects. The majority of cancerous urine samples showed MMP-9 lytic activity but only a few contained MMP-2. Moreover, MMP-9 content is enhanced in the urine from patients with high-grade and advanced-stage bladder tumors. Finally, we determined the urinary levels of urinary bladder cancer (UBC), tissue polypeptide-specific antigen (TPS) and protein 22 of nuclear matrix (NMP22). The levels of TPS and NMP-22 were higher in G3 bladder cancer than in G1 and G2 neoplasias. The urinary values of these two biomarkers correlated with the increase in MMP-9 lytic activity in high-grade and advanced-stage bladder cancer.
Similar articles
-
Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers.Clin Cancer Res. 2000 Jun;6(6):2333-40. Clin Cancer Res. 2000. PMID: 10873084
-
Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine.Eur Urol. 2007 Nov;52(5):1388-96. doi: 10.1016/j.eururo.2007.04.006. Epub 2007 Apr 10. Eur Urol. 2007. PMID: 17466450
-
Alteration in urinary matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio predicts recurrence in nonmuscle-invasive bladder cancer.Clin Cancer Res. 2003 Jul;9(7):2576-82. Clin Cancer Res. 2003. PMID: 12855633
-
Matrix metalloproteinases and bladder cancer.J Med Invest. 2001 Feb;48(1-2):31-43. J Med Invest. 2001. PMID: 11286015 Review.
-
Urine: beyond cytology for detection of malignancy.Diagn Cytopathol. 2002 Sep;27(3):139-42. doi: 10.1002/dc.10135. Diagn Cytopathol. 2002. PMID: 12203859 Review.
Cited by
-
Network Pharmacology Combined with Bioinformatics Analysis to Texplore the Potential Mechanism of Phellodendri Chinensis Cortex Against Bladder Cancer.Cell Biochem Biophys. 2024 Dec;82(4):3317-3331. doi: 10.1007/s12013-024-01414-6. Epub 2024 Jul 18. Cell Biochem Biophys. 2024. PMID: 39023680
-
Matrix Metalloproteinases and Bladder Cancer: What is New?ISRN Urol. 2012;2012:581539. doi: 10.5402/2012/581539. Epub 2012 Jul 17. ISRN Urol. 2012. PMID: 22852097 Free PMC article.
-
Electrochemiluminescence bioassay with anti-fouling ability for determination of matrix metalloproteinase 9 secreted from living cells under external stimulation.Mikrochim Acta. 2023 Sep 29;190(10):422. doi: 10.1007/s00604-023-05996-5. Mikrochim Acta. 2023. PMID: 37775573
-
Evaluation of hTERT, KRT7, and survivin in urine for noninvasive detection of bladder cancer using real-time PCR.BMC Urol. 2021 Apr 19;21(1):64. doi: 10.1186/s12894-021-00838-z. BMC Urol. 2021. PMID: 33874920 Free PMC article.
-
RNAi-mediated abrogation of cathepsin B and MMP-9 gene expression in a malignant meningioma cell line leads to decreased tumor growth, invasion and angiogenesis.Int J Oncol. 2007 Nov;31(5):1039-50. Int J Oncol. 2007. PMID: 17912429 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous